Events - Spark Newswire

5 minute read

Chinook Therapeutics Presents Updated Data From Atrasentan Phase 2 AFFINITY IgA Nephropathy Patient Cohort, Preclinical Atrasentan Research And Ongoing Clinical Trials At The American Society Of Nephrology Kidney Week 2022

November 3, 10:07 AM

Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at

KDNY

4 minute read

Kezar Life Sciences Presents Complete Results From The MISSION Phase 2 Trial Evaluating Zetomipzomib In Lupus Nephritis At ASN’s Kidney Week 2022 Annual Meeting

By Benzinga Newsdesk

November 3, 10:01 AM

Zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25. This benefit occurred with a 53% mean

KZR

1 minute read

Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting

By Benzinga Newsdesk

November 3, 9:51 AM

Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its CDC7 inhibitor,

SDGR

4 minute read

Biomea Fusion To Present Preclinical Data For BMF-500, An Investigational Oral Covalent FLT3 Inhibitor, At The 64th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

November 3, 9:49 AM

BMF-500, an investigational third generation covalent FLT3 inhibitor, has demonstrated preclinically that it may be the most potent and selective inhibitor of FLT3 evaluated to date: Greater Cytotoxicity: In acute

BMEA

2 minute read

Harpoon Therapeutics To Present Interim Results From Phase 1 Clinical Trial Of T Cell Engager HPN217 At The 64th ASH Annual Meeting And Exposition

By Benzinga Newsdesk

November 3, 9:43 AM

Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present updated interim data from its Phase 1 clinical trial evaluating

HARP

1 minute read

SELLAS Life Sciences To Present Data On Its Highly Selective CDK9 Inhibitor, GFH009, At The 2022 American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

November 3, 9:37 AM

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad

SLS

1 minute read

Syros Pharmaceuticals To Present Initial Data From SELECT-AML-1 Phase 2 Trial At 64th ASH Annual Meeting

By Benzinga Newsdesk

November 3, 9:22 AM

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing

SYRS

1 minute read

CRISPR Therapeutics Announces Poster Presentation On CTX110 At American Society Of Hematology (ASH) 2022 Annual Meeting

By Benzinga Newsdesk

November 3, 9:12 AM

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110®, its wholly-owned

CRSP

1 minute read

Turquoise Hill Announces Postponement Of The Special Meeting Regarding Proposed Arrangement With Rio Tinto To November 8, 2022

By Benzinga Newsdesk

November 1, 9:58 AM

The Special Meeting of Turquoise Hill shareholders is postponed to 10:30 a.m. (Eastern time) November 8, 2022 at the request of Rio Tinto Deadline to vote by proxy is extended to 10:30 a.m. (Eastern time) on November

RIO

1 minute read

Intellia Therapeutics To Present Updated Interim Clinical Data From Ongoing Phase 1/2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2022 ACAAI Annual Scientific Meeting

By Benzinga Newsdesk

October 31, 7:32 AM

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract

NTLA